Lars Ynddal

699 total citations
18 papers, 484 citations indexed

About

Lars Ynddal is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Cellular and Molecular Neuroscience. According to data from OpenAlex, Lars Ynddal has authored 18 papers receiving a total of 484 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Cellular and Molecular Neuroscience. Recurrent topics in Lars Ynddal's work include Growth Hormone and Insulin-like Growth Factors (5 papers), Receptor Mechanisms and Signaling (5 papers) and Peroxisome Proliferator-Activated Receptors (4 papers). Lars Ynddal is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (5 papers), Receptor Mechanisms and Signaling (5 papers) and Peroxisome Proliferator-Activated Receptors (4 papers). Lars Ynddal collaborates with scholars based in Denmark, Switzerland and United States. Lars Ynddal's co-authors include Steen Honoré Hansen, John P. Mogensen, Jan Fleckner, Erik Max Wulff, Lone Jeppesen, Ingrid Pettersson, Per Sauerberg, Christian L. Brand, L. Anders Svensson and Paul S. Bury and has published in prestigious journals such as Scientific Reports, Journal of Medicinal Chemistry and Journal of Chromatography A.

In The Last Decade

Lars Ynddal

18 papers receiving 480 citations

Peers

Lars Ynddal

EDM

SURGE

PHYSI

Holger Heitsch Germany

Net Daş-Evcimen Türkiye

Angela Dudda Germany

Paolo Barassi Italy

Michael E. Beil Switzerland

Manoja K. Brahma United States

Ellen V. Cryan United States

Yoshimitsu Komatsu Japan

Suresh Giri India

Kazimir Sestanj United States

Holger Heitsch Germany

Lars Ynddal

277 ×0.9

229 ×1.8

EDM

52 ×0.7

SURGE

72 ×1.0

PHYSI

106 ×1.5

Citations per year, relative to Lars Ynddal Lars Ynddal (= 1×) peers Holger Heitsch

Countries citing papers authored by Lars Ynddal

Since Specialization

Citations

This map shows the geographic impact of Lars Ynddal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Ynddal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Ynddal more than expected).

Fields of papers citing papers by Lars Ynddal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Ynddal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Ynddal. The network helps show where Lars Ynddal may publish in the future.

Co-authorship network of co-authors of Lars Ynddal

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Ynddal. A scholar is included among the top collaborators of Lars Ynddal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Ynddal. Lars Ynddal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Østergaard, Søren, Carsten Jessen, Johan F. Paulsson, et al.. (2025). Variant screening of PYY _3–36 leads to potent long-acting PYY analogs with superior Y ₂ receptor selectivity. Science Translational Medicine. 17(791). eadq6392–eadq6392. 3 indexed citations

Østergaard, Søren, Johan F. Paulsson, Jacob Kofoed, et al.. (2021). The effect of fatty diacid acylation of human PYY3-36 on Y2 receptor potency and half-life in minipigs. Scientific Reports. 11(1). 21179–21179. 33 indexed citations

Madsen, Peter, János T. Kodra, Carsten Behrens, et al.. (2009). Human Glucagon Receptor Antagonists with Thiazole Cores. A Novel Series with Superior Pharmacokinetic Properties. Journal of Medicinal Chemistry. 52(9). 2989–3000. 26 indexed citations

Lau, Jesper, Carsten Behrens, Ulla G. Sidelmann, et al.. (2007). New β-Alanine Derivatives Are Orally Available Glucagon Receptor Antagonists. Journal of Medicinal Chemistry. 50(1). 113–128. 44 indexed citations

Sauerberg, Per, Grith Skytte Olsen, Lone Jeppesen, et al.. (2007). Identification and Synthesis of a Novel Selective Partial PPARδ Agonist with Full Efficacy on Lipid Metabolism In Vitro and In Vivo. Journal of Medicinal Chemistry. 50(7). 1495–1503. 18 indexed citations

Nielsen, Flemming, Lars Ynddal, Thora Bödvarsdóttir, et al.. (2006). New 3-Alkylamino-4H-thieno-1,2,4-thiadiazine 1,1-Dioxide Derivatives Activate ATP-Sensitive Potassium Channels of Pancreatic Beta Cells. Journal of Medicinal Chemistry. 49(14). 4127–4139. 23 indexed citations

Ynddal, Lars & Steen Honoré Hansen. (2003). On-line turbulent-flow chromatography–high-performance liquid chromatography–mass spectrometry for fast sample preparation and quantitation. Journal of Chromatography A. 1020(1). 59–67. 29 indexed citations

Mackay, P., Lars Ynddal, Jan Vanggaard Andersen, & J G McCormack. (2003). Pharmacokinetics and anti‐hyperglycaemic efficacy of a novel inhibitor of glycogen phosphorylase, 1,4‐dideoxy‐1,4‐imino‐d‐ arabinitol, in glucagon‐challenged rats and dogs and in diabetic ob/ob mice. Diabetes Obesity and Metabolism. 5(6). 397–407. 18 indexed citations

Mogensen, John P., Lone Jeppesen, Paul S. Bury, et al.. (2003). Design and synthesis of novel PPARα/γ/δ triple activators using a known PPARα/γ dual activator as structural template. Bioorganic & Medicinal Chemistry Letters. 13(2). 257–260. 23 indexed citations

10.

Sauerberg, Per, Paul S. Bury, John P. Mogensen, et al.. (2003). Large Dimeric Ligands with Favorable Pharmacokinetic Properties and Peroxisome Proliferator-Activated Receptor Agonist Activity in Vitro and in Vivo. Journal of Medicinal Chemistry. 46(23). 4883–4894. 28 indexed citations

11.

Nielsen, Flemming, Thora Bödvarsdóttir, Anne Worsaae, et al.. (2002). 6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-Dioxide Derivatives Potently and Selectively Activate ATP Sensitive Potassium Channels of Pancreatic β-Cells. Journal of Medicinal Chemistry. 45(19). 4171–4187. 40 indexed citations

12.

Sauerberg, Per, Ingrid Pettersson, Lone Jeppesen, et al.. (2002). Novel Tricyclic-α-alkyloxyphenylpropionic Acids: Dual PPARα/γ Agonists with Hypolipidemic and Antidiabetic Activity. Journal of Medicinal Chemistry. 45(4). 789–804. 126 indexed citations

13.

Zdravković, Marija, Lise Eliot, Mikael S. Thomsen, et al.. (2001). The pharmacokinetics, pharmacodynamics, safety and tolerability following 7 days daily oral treatment with NN703 in healthy male subjects. Growth Hormone & IGF Research. 11(1). 41–48. 9 indexed citations

14.

Ynddal, Lars, et al.. (2001). Pharmacokinetic and Pharmacodynamic Modeling of NN703, a Growth Hormone Secretagogue, after a Single po Dose to Human Volunteers. The Journal of Clinical Pharmacology. 41(2). 163–169. 9 indexed citations

15.

Zdravković, Milan, Birgitte Søgaard, Lars Ynddal, et al.. (2000). The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN703, a novel orally active growth hormone secretagogue in healthy male volunteers. Growth Hormone & IGF Research. 10(4). 193–198. 13 indexed citations

16.

Gobburu, Jogarao, Henrik Agersø, William J. Jusko, & Lars Ynddal. (1999). Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers. Pharmaceutical Research. 16(9). 1412–1416. 18 indexed citations

17.

Ynddal, Lars, et al.. (1998). Ipamorelin — A novel very potent growth hormone secretagogue. Growth Hormone & IGF Research. 8(4). 332–332. 2 indexed citations

18.

Karlsson, Per, et al.. (1995). Oral administration of NNC 756 — a placebo controlled PET study of D1-dopamine receptor occupancy and pharmacodynamics in man. Psychopharmacology. 119(1). 1–8. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact